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Abstract
MLL2 mutations are detected in 55 to 80% of patients with Kabuki syndrome (KS).
In 20 to 45% patients with KS, the genetic basis remains unknown, suggesting
possible genetic heterogeneity. Here, we present the largest yet reported cohort
of 116 patients with KS. We identified MLL2 variants in 74 patients, of which
47 are novel and a majority are truncating. We show that pathogenic missense
mutations were commonly located in exon 48. We undertook a systematic
facial KS morphology study of patients with KS at our regional dysmorphology
meeting. Our data suggest that nearly all patients with typical KS facial features
have pathogenic MLL2 mutations, although KS can be phenotypically variable.
Furthermore, we show that MLL2 mutation-positive KS patients are more likely
to have feeding problems, kidney anomalies, early breast bud development,
joint dislocations and palatal malformations in comparison with MLL2 mutation-
negative patients. Our work expands the mutation spectrum of MLL2 that...
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MLL2 mutations are detected in 55 to 80% of patients with Kabuki syndrome (KS). In 20 to 45% patients with KS, the genetic
basis remains unknown, suggesting possible genetic heterogeneity. Here, we present the largest yet reported cohort of 116 patients
with KS. We identified MLL2 variants in 74 patients, of which 47 are novel and a majority are truncating. We show that pathogenic
missense mutations were commonly located in exon 48. We undertook a systematic facial KS morphology study of patients with
KS at our regional dysmorphology meeting. Our data suggest that nearly all patients with typical KS facial features have pathogenic
MLL2 mutations, although KS can be phenotypically variable. Furthermore, we show that MLL2 mutation-positive KS patients
are more likely to have feeding problems, kidney anomalies, early breast bud development, joint dislocations and palatal
malformations in comparison with MLL2 mutation-negative patients. Our work expands the mutation spectrum of MLL2 that may
help in better understanding of this molecule, which is important in gene expression, epigenetic control of active chromatin
states, embryonic development and cancer. Our analyses of the phenotype indicates that MLL2 mutation-positive and -negative
patients differ systematically, and genetic heterogeneity of KS is not as extensive as previously suggested. Moreover, phenotypic
variability of KS suggests that MLL2 testing should be considered even in atypical patients.
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INTRODUCTION
Kabuki syndrome (KS, Kabuki make-up syndrome or Niikawa–Kuroki
syndrome) is an autosomal dominant condition that arises de novo in
a majority of cases and is characterised by a recognisable facial pheno-
type of interrupted high-arched eyebrows, long palpebral fissures,
eversion of lateral part of lower eyelids, broad depressed nasal tip, large
prominent earlobes and pillowed lower lip.1,2 All children with KS are
globally delayed and have mild-to-moderate learning disability (for
review of clinical features, see Adam and Hudgins3). They also have a
high incidence of internal malformations, involving, but not limited
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to, the heart, kidneys, gastrointestinal system, skeletal system and eyes.
KS is commonly associated with severe feeding difficulties, hypotonia,
postnatal failure to thrive, obesity in later childhood and frequent
infections. Rare problems include idiopathic thrombocytopenic pur-
pura, seizures, autistic traits, delayed puberty and tumours.
Recently, whole exome sequencing led to the identification of
mutations in MLL2 as the basis of KS in a majority of the patients.4
Still, the underlying cause cannot be identified in 20 to 45% of
patients with a presumed diagnosis of KS, suggesting possible genetic
heterogeneity.5–8 To investigate the spectrum of mutations associated
with KS, we sequenced MLL2 in 116 patients with clinically suspected
KS. To test if KS is genetically heterogeneous, we systematically
evaluated differences between the phenotype of patients in whom
MLL2 mutations were found versus those in whom mutations were
not detected.
PATIENTS AND METHODS
Patient ascertainment
Before the discovery of MLL2 mutations as a cause of KS, we had ascertained a
highly selected group of B35 patients, based on clinical features and facial
dysmorphology, through the Clinical Genetics clinics in Manchester. Of these
35 patients, 18 were included in the study reported by Hannibal et al.8 After the
gene discovery, we expanded our cohort by accepting patients with possible KS
from Clinical Genetics departments, mostly across the United Kingdom.
Referring clinicians were asked to provide DNA samples from their patients
and, if possible/required, from both parents. A clinical proforma was designed
to gather phenotypic information from the referring clinicians. Photographs of
patients were also collected wherever possible. The study was approved by the
Central Manchester Research Ethics Committee (02/CM/238) and the Uni-
versity of Manchester Ethics Committee. Fully informed signed consents were
taken from legal guardians of the patients by the referring clinicians. The study
was performed in accordance with the Declaration of Helsinki protocol.
Mutation screening of MLL2 gene
All the patients were screened for mutations in the MLL2 gene. PCR
amplification for all the 54 exons spanning the MLL2 gene was performed
using primer sequences and the PCR conditions previously described.4 PCR
amplification was carried out on Veriti thermal cycler or 2720 thermal cycler
(Applied Biosystems, Paisley, UK) using the Reddy Mix Custom PCR Master
Mix (ABgene, Epsom, UK, catalogue no: AB-0575/DC/LD/b) according to the
manufacturer’s instructions. Amplified products were cleaned using Agencourt
AMPure XP (Beckman Coulter Genomics, Takeley, UK) system on an
automated Beckman Coulter Liquid Handler, Biomek 3000, as per the
manufacturer’s instructions. The purified PCR products were then subjected
to direct sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems). All the sequencing reactions were cleaned using
Agencourt CleanSeq on automated Beckman Coulter Liquid Handler and were
then sequenced in the departmental core facility on an ABI prism 3100 Genetic
Analyser (Applied Biosystems). The sequence data generated were exported and
analysed graphically using the DNA sequence analysis software, STADEN
(http://staden.sourceforge.net/). The changes observed were checked against
the NCBI SNP database to identify known single-nucleotide polymorphisms
(SNPs). Sequence variations found were reported according to the Human
Genome Variation Society nomenclature. Where available, DNA from the
parents of the patients with mutations was screened to investigate if the change
was de novo or inherited.
All the mutations that were identified in this study and in our patients
reported by Hannibal et al8 were independently confirmed. We designed new
primer sets for this step to avoid amplicons of 4700 base pairs. These primer
sequences are available on request.
Facial KS morphology score
Clinical geneticists and dysmorphologists from Manchester, Liverpool, Leeds,
Newcastle upon Tyne, Sheffield and Cardiff meet six monthly in Manchester at
‘M62 dysmorphology meeting’ to discuss unusual cases. We decided to test if
facial dysmorphism can be a reliable predictor of MLL2 mutation status in our
cohort. We showed 37 facial photographs of 33 patients from our cohort to
23 dysmorphologists who had gathered for the M62 meeting in June 2011.
Photographs for 15 MLL2-negative patients were available. Photographs of all
these 15 patients were included in the study to eliminate selection bias and
provide enough statistical power. Although more photographs of patients with
definite MLL2 mutation were available, only 18 were included in the study.
This was done to ensure that the presentation lasted for o10 min to avoid
participant boredom that could adversely affect the results. Majority of the
photographs for MLL2 mutation-positive patients were selected randomly, but
some with atypical appearance were included intentionally to test the whole
spectrum of facial dysmorphism of KS. Participants were blind to clinical
histories and mutation status of the patients. Each photograph was shown for
15 s and participants were asked to rate the likelihood of the patient having KS
on an ordinal scale of one to five (one for ‘unlikely KS’, three for ‘possible KS’
and five for ‘definite KS’). The results were analysed using Mann–Whitney test.
To assess if facial KS morphology scores were age dependent, we included two
photographs taken at different ages for four patients.
Genotype–phenotype analysis
Detailed information on clinical features was available for 63/116 patients
(40 MLL2 mutation positive and 23 MLL2 mutation negative). We concen-
trated on analysing differences between those features where information was
reliably quantifiable and was available in majority of the cases. Therefore, we
did not analyse differences between growth, developmental delay and learning
disability. Two-tailed P-values were generated by Fisher’s exact test.
RESULTS
Mutation analysis
We sequenced all 54 exons and the exon–intron boundaries in 98
patients with a suspected diagnosis of KS. For the purpose of analysis,
we have also included results from our additional 18 patients (giving a
total of 116) who have already been reported by Hannibal et al.8 All
the patients previously reported in another study have been identified
clearly in the comments box of each table (Supplementary Tables 1–4).
We ascribed ‘definite pathogenicity’ only to mutations resulting in
truncated protein or obvious splicing error or missense changes that
were proven to be de novo in at least one patient. If both parental
samples were unavailable, a missense change was considered to be
‘likely pathogenic’ if it has been identified in more than one patient
and in silico predictions indicated high degree of conservation and
disruption of protein function. Changes that were inherited from an
unaffected parent or found concurrently in the same patient with an-
other definitely pathogenic variant were assigned as ‘unlikely pathogenic’.
Changes that could not be qualified to any of these categories were
labelled to be of ‘uncertain pathogenicity’.
Following our criteria, no pathogenic variants were found in 42/116
(36.2%) patients. In 74/116 (63.8%) patients, we identified MLL2
variants, out of which 66 variants were inferred to be definite disease
causing and 2 to be likely pathogenic (Figure 1). We could not be
certain of the significance of six changes. Out of 74 changes, 25 were
nonsense mutations, 21 were frameshift deletions, 9 were frameshift
insertions, 10 were splice-site variants, 9 were missense changes and
2 were in-frame deletions. Both the changes classified as likely
pathogenic were missense changes. Out of six changes with uncertain
significance, two potentially affected splicing and four were missense
changes. In addition, 47 changes were novel variants.
Facial KS morphology scores
Mean and median values for facial KS morphology scores were
calculated for each patient. We considered an average score of 43.5
and o3 as being indicative of features highly compatible or incompa-
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tible with KS, respectively. For scores between 3 and 3.5, we assumed
that facial dysmorphism was not enough to strongly suggest or reject
KS as a diagnosis for the individual.
Table 1 provides a summary of facial KS morphology scores in all 33
patients. Our analysis showed that 13/15 MLL2 mutation-negative
patients had a mean score of o3 for facial KS morphology, whereas
12/18 MLL2 mutation-positive patients scored 43.5. Although there
is some overlap between the scores of two groups, the difference
between facial KS morphology scores of MLL2 mutation-positive and
-negative KS patients was highly significant, with the P-value ofo0.0001.
Genotype–phenotype correlation
We analysed our phenotype data to investigate if there were any
differences between other clinical features of MLL2 mutation-positive
and -negative groups. The results showed that feeding problems,
urogenital anomalies, early breast buds, joint dislocations and cleft
palate were significantly more common in patients with MLL2 muta-
tions (Table 2).
DISCUSSION
MLL2 is a histone H3 lysine 4 (H3K4)-specific methyl transferase that
belongs to the SET1 family of human SET-domain protein methyl-
transferase superfamily.9,10 It is a large protein that consists of seven
plant homeodomains (PHD, for protein–protein interaction), one
high-mobility group domain (for binding to DNA with low sequence
specificity), five LXXLL motifs (for interaction with nuclear recep-
tors), one each FYRC and FYRN domains (for heterodimerisation
between terminal fragments of MLL) and a single SET domain (for
histone lysine methylation) (Figure 1).10 MLL2 functions as a part of
multiprotein complex, ASCOM, which binds to the regulatory sites of
the target genes.11 It is important for epigenetic transcriptional acti-
vation, it interacts with oestrogen receptor-a and is important for
embryonic development.9,12
We identified variants in 74/116 (63.8%) patients with KS in our
study (Figure 1). Ng et al4 discovered mutations in 35/53 (66%) cases
of KS through a combination of exome and Sanger sequencing.
Paulussen et al,5 Li et al6 and Micale et al7 identified MLL2 mutations
in 34/45 (75.5%), 19/34 (55.8%) and 45/62 (72.5%) patients, respec-
tively. Most recently, Hannibal et al8 reported 57 more patients with
KS and found mutations in 46 individuals (80%), including 17 of our
18 patients. We present here the largest cohort of MLL2 mutation-
positive patients with KS identified as yet. Overall mutation detection
rate between different studies is variable, which is likely a reflection of
differences in ascertainment.
Including this study, there are now 232 KS kindreds with MLL2
mutations in the published literature. We have analysed the MLL2
mutation spectrum by combining our data with what is already published.
Truncating mutations
Out of 232 published MLL2 mutation-positive KS patients, including
55 patients reported here, 170 (73.2%) have truncating mutations
(Supplementary Table 1). A number of these mutations have now
been reported in more than one patient and are highlighted in the
Supplementary Table 1.
Out of 170, 86 (more than half) are nonsense mutations. In
addition, 59 patients have deletions, with the majority of a single
base. The biggest reported deletion is of 32 bases. Notably,
c.6595delT (p.Y2199IfsX65) in exon 31 has been described in
five patients, including two patients in our study. It has been shown
to be de novo in three patients, confirming that it is a recurrent
Figure 1 Spectrum of MLL2 mutations. Schematic representation of MLL2
mutations identified in this study. The gene structure shows all 54 coding
exons and the protein structure shows the protein domains and motifs.
Arrows indicate the exonic location of the mutations identified in the
patients. Nonsense mutations are shown in red, frameshift in/dels are shown
in green, splice-site mutations are shown in blue and missense mutations
and in-frame deletions are shown in purple. Novel variants are underlined
and variants of uncertain pathogenicity are highlighted by *.
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mutation. Also, 22 patients have small duplications or insertions.
Three patients have complicated insertion and duplication, with two
involving exon 34.
Of note, a number of exons are disproportionately affected by
truncating mutations. For example, exon 52, which codes for
0.44% of the translated transcript, accounts for three mutations in
four patients, more than five times the expected rate. Exons 27, 33,
40 and 53 also account for excessively large number of truncating
mutations, although the sample size is insufficient to draw statistical
conclusions.
The largest numbers of truncating mutations have been found in
exon 39 (36 mutations in 39 patients) and exon 48 (16 mutations in
21 patients). Exons 39 and 48 code for 16.8 and 6.9% of MLL2
protein, correspondingly. The truncating mutation closest to N and C
terminals of the protein are p.C158VfsX50 (exon 4) and p.R5501X
(exon 53).
Splice-site mutations
We have added 10 splice-site mutations (9 novel) to the list of MLL2
mutations. Including patients described in our study, 21 splice-site
mutations are now described in patients with KS (Supplementary
Table 2). One patient in our study has a deletion spanning from the
end of exon 49 to 10 bases into the intron, resulting in deletion of a
single amino acid and abolishment of a splice donor site. Out of
19 MLL2 splice-site mutations, 7 have been shown to be de novo. Out
of 10 splice variants, 2 are of uncertain pathogenicity. Resultant
proteins of none of the MLL2 splice-site mutations have been
characterised as yet. There are no obvious phenotypic differences
between patients with splice-site and other mutations. Notably, one
patient with c.13999+1G developed low-grade myofibrosarcoma and
has been reported earlier.13
Nontruncating mutations
A total of 28 missense or in-frame insertions or deletions in MLL2,
including 9 in this study, have been reported in 37 patients with KS. In
our study, only those nontruncating changes that were proven to be
de novo in at least one patient were considered to be definitely
pathogenic. Using the same criteria in all the reported mutations,
we can be certain about deleterious effect of 13 mutations in 22
patients (Supplementary Table 3). In 15 patients, 15 changes have not
Table 1 Facial KS morphology scores
Average
Photograph number MLL2 mutation status Patient number Type of mutation Total score (max 115) Mean Median
14 + KS86 Frameshift insertion 113 4.91 5
23 + KS49 Frameshift deletion 103 4.48 5
32 + KS33 Nonsense 103 4.48 5
20 + KS55 Frameshift insertion 102 4.43 5
17 + KS82 Frameshift deletion 101 4.39 5
15 + KS85 Frameshift deletion 100 4.35 4
1 + KS01 Frameshift deletion 98 4.26 4
8 + KS100 Frameshift deletion 95 4.13 4
10 + KS06 Frameshift deletion 94 4.09 4
33 + KS30 Missense 92 4 4
28 + KS38 Frameshift insertion 84 3.65 4
5 + KS03 Nonsense 81 3.52 4
3 + KS45 Frameshift deletion 78 3.39 4
25 + KS48 Frameshift deletion 78 3.39 3
21 + KS51 Nonsense 70 3.04 3
30 + KS36 Nonsense 58 2.52 2
35 + KS62 Frameshift deletion 57 2.48 2
39 + KS67 Frameshift insertion 57 2.48 2
34  KS110 NA 93 4.04 4
4  KS02 NA 75 3.26 3
7  KS90 NA 64 2.78 3
12  KS111 NA 64 2.78 3
37  KS64 NA 61 2.65 3
22  KS66 NA 59 2.56 2
24  KS115 NA 59 2.56 3
40  KS68 NA 59 2.56 3
6  KS05 NA 57 2.48 2
31  KS35 NA 55 2.39 2
9  KS63 NA 55 2.39 2
26  KS46 NA 52 2.26 2
2  KS89 NA 47 2.04 2
29  KS37 NA 44 1.91 2
18  KS59 NA 39 1.69 2
Abbreviation: NA, not applicable. The table is sorted as per MLL2 mutation status and then by descending total scores.
The statistical test was performed on individual scores given by each participant to each patient but only the total, mean and median scores are presented here.
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been checked for inheritance. It is therefore not possible to be certain
about their pathogenicity.
Out of these 28 changes, one is a duplication of two amino
acids resulting from a six base pair duplication in exon 48.7
p.I5497del, a single amino-acid deletion within the SET domain
resulting from a mutation in exon 53, has been described in three
patients, including one in this study. In our patient, this change was
shown to be de novo and hence certainly pathogenic. Other 26/28
changes are missense.
Most of the pathogenic missense changes are concentrated toward
the COOH terminal of the protein. Out of the 37 (43.2%) patients
with non-truncating non-splice-site mutations, 16 have changes in
exon 48 (that codes for o7% of MLL2 protein). Five missense
mutations in exon 48 have been described in more than one patient.
This includes p.R5048C mutation that we found in a previously
reported mother–daughter pair.14 Of note, exon 48 codes for LXXL
motifs, one PHD domain and part of the FYRN domain.
We have also compiled a list of changes that are not known
polymorphisms but have been seen concurrently in patients who
have another definite pathogenic mutation (Supplementary Table 4).
These are unlikely to be pathogenic but may be useful in under-
standing the role of various MLL2 residues. In this list we have also
included variants that have been shown to be inherited from a normal
parent. In our opinion, in the absence of stronger evidence to suggest
variable penetrance in KS, such variants should be provisionally con-
sidered as benign. This degree of caution is especially important in
clinical practice. Of note, four out of the five variants that we found
concurrently with another definitely pathogenic mutation in this
study are predicted to be highly damaging by AlignGVD and SIFT.
This shows that in silico predictions for MLL2 are currently not
entirely reliable, which is probably because the structure of MLL2
has not yet been realised. Hence, in a patient with KS, it is important
to establish that a missense MLL2 change has arisen de novo before
ascribing definite pathogenicity.
Facial KS morphology scores
Our group had contributed 18 patients to the study reported by
Hannibal et al8 and, interestingly, MLL2 mutations were found in 17/
18 patients (94.4%). Notably, these 18 patients were selected for
having clinical features that are considered to be most typical of KS.
The characteristics of mutations found in this group did not differ in
any way from the larger cohort. Most previous studies have proposed
that KS is genetically heterogeneous, but our experience indicates
that most typical cases of KS are indeed due to MLL2 mutations.
Furthermore, no strong genotype–phenotype correlation has emerged
in previous studies comparing MLL2 mutation-positive and -negative
patients. We hypothesised that facial KS morphology might be the
most important difference between the two groups. We undertook a
systematic approach to score facial KS morphology to test the genetic
heterogeneity of ‘true’ KS.
Results of our facial KS morphology scores show that nearly all
patients with ‘typical Kabuki face’ have mutations in MLL2
(Figures 2a, b and Table 1). Furthermore, there was no apparent
trend correlating facial KS morphology scores with the type of
mutation seen. Only 1 out of 15 MLL2 mutation-negative KS patients
(KS110) scored high on the facial KS morphology score (93/115, mean
4.04; Figure 2d). Clinical history of this patient was also reminiscent of
typical KS. Further work is needed to identify the underlying
molecular mechanism in this child. Overall, this shows that based
on facial dysmorphism, genetic heterogeneity of KS is not likely to be
as large as previously expected.
A few patients who had relatively low facial KS morphology scores
are not absolutely facially typical for KS but still have MLL2 mutations,
demonstrating variability of facial phenotype in KS (see KS 62 and 36
in Table 1; Figure 2c). This indicates that MLL2 testing should be
considered even in atypical KS patients.
In our and other geneticists’ experience, it can be difficult to
recognise KS in early infancy and in adulthood. Interestingly, for
four patients whose two photographs taken at different ages were
included in the slide show (Figures 3a–d), the scores for early child-
hood photographs corresponded better to the mutation status than
those taken in infancy or adulthood.
Overall, the relationship between facial dysmorphism and MLL2
mutation status seems compelling, but these results should be interpreted
with caution because by nature, such studies are subjective and open
to many biases.
Genotype–phenotype correlation
Our finding of significant differences between feeding difficulties, early
breast bud development or gynaecomastia, joint dislocations and cleft
palate adds further to help delineate features that may increase the
chances of finding MLL2 mutation in a patient (Table 2). Similar to
two previous studies,6,8 we also observed significant differences in
rates of urogenital malformations. The range of feeding difficulties in
MLL2 mutation-positive patients varied from just slow feeding or
gastro-oesophageal reflux to needing nasogastric tube feeding
and/or even gastrostomy. Most frequent joint dislocations were
reported to involve the patella, hips, shoulders and elbows. One
patient had bilateral thumb subluxations. A variety of palatal
malformations like bifid or absent uvula, velopharyngeal insufficiency
and central or bilateral cleft palate were seen in MLL2 mutation-
positive patients.
Table 2 Genotype–phenotype differences between MLL2 mutation-positive and -negative cases
MLL2 status
Clinical feature
status
Cardiac
defects
Kidney
abnormalities
Cleft
palate
Joint
dislocations
Feeding
problems
Early breast buds/
gynaecomastia
Repeated
infections
Mutation positive (n1¼40) Present 15 16 17 13 32 16 25
Not present 24 23 23 27 4 23 12
Data not available 1 1 0 0 4 1 2
Mutation negative (n2¼23) Present 10 3 3 2 12 1 14
Not present 13 20 20 21 11 22 19
Data not available 0 0 0 0 0 0 0
P-value 0.7909 0.0248 0.0236 0.0369 0.0024 0.0024 0.7812
Statistically significant P-values are in bold.
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MLL2 mutation-negative patients
Deep intronic mutations, large intragenic deletions or duplications or
changes affecting the regulatory elements may not be recognised by
sequencing of exons and exon–intron boundaries. Perhaps, MLPA or
mRNA sequencing should be considered in typical MLL2 mutation-
negative KS patients. However, from the facial KS morphology scores
and emerging genotype phenotype correlation, it seems likely that
many suspected KS patients without MLL2 mutation are likely to have
unrelated conditions that may not be due to defects even in the same
pathway. This is further indicated by the failure to find mutations
in any genes associated with ASCOM complex in MLL2 mutation-
negative patients in two other studies.6,8
Four MLL2 mutation-negative patients with proposed KS in the
study reported by Hannibal et al8 were found to have an alternative
diagnosis by array comparative genomic hybridisation (a-CGH). One
patient had a deletion on 5q encompassing NSD1, the second had a
novel 19q23 deletion involving 20 genes, the third had a complex
translocation involving chromosomes 8 and 18 and the fourth patient
had mosaic trisomy 12. In our cohort we have not systematically
performed a-CGH on all MLL2 mutation-negative patients but have
found a deletion of 6q13, inherited from her affected mother, in one
patient who we have always regarded to have atypical KS. Her
mother also has similar clinical features. Similar deletions have
been described in the literature.15 We therefore suggest a-CGH
Figure 2 Facial features of patients in this study. (a) Facial photograph of KS49, who has a MLL2 mutation, showing typical facial features of KS with
interrupted high-arched eyebrows, long palpebral fissures, eversion of lateral part of lower eyelids, broad depressed nasal tip, large prominent earlobes and
pillowed lower lip. (b) Facial photograph of KS45, who has a MLL2 mutation, showing deficient lateral eyebrows, long palpebral fissures, broad depressed
nasal tip, large prominent earlobes, pillowed lower lip and oligodontia. (c) Facial photograph of KS36, who has a MLL2 mutation but is facially not typical for
Kabuki syndrome. This demonstrates phenotypic variability of this condition indicating that MLL2 testing may be considered even in atypical patients.
(d) Facial phenotype of KS110, which is typical of KS but MLL2 mutation was not found. She also has a history of severe feeding difficulties in infancy,
coarctation of aorta, hypoplastic left ventricle, ventricular septal defect, aortic and sub-aortic stenosis, bilateral mild hydronephrosis, deep labial adhesions,
right iris coloboma, bilateral choroido-retinal colobomas, single duplicated tooth, hypotonia and mild developmental delay.
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should be considered in MLL2 mutation-negative KS patients, if
not done already.
CONCLUSIONS
Our work expands the known mutation spectrum of MLL2 mutations
associated with KS. We have shown that the majority of mutations are
truncating and the pathogenic missense mutations are commonly
located in exon 48. We suggest that caution should be practised in
assigning pathogenicity to missense MLL2 variants. Our compilation
of mutation data available from the published literature may help
laboratories offering MLL2 testing to ascribe significance to novel
findings. Our mutation detection rate of B60% is a closer reflection
of expected rate in clinical setting. Overall, this may provide insight
into the structure and function of MLL2.
We show that KS can be phenotypically variable and therefore
MLL2 testing should be considered even in atypical KS patients.
Furthermore, we have demonstrated that MLL2 mutation-positive
and -negative patients differ significantly in their facial dysmorphism
and some clinical features. The majority of typical KS patients have
MLL2 mutations, implying that the genetic heterogeneity of KS may
be minimal. This work will also help in further studies to identify the
genetic basis of patients with MLL2 mutation-negative KS.
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